Histiocytic Disorders, Malignant clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
open to all eligible people
This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment. Cobimetinib blocks activation of a protein called Mitogen-activated protein kinase (MEK) that is part of incorrect growth signals in histiocytosis cells. Four different groups of patients will be enrolled.
at UCSF
Our lead scientists for Histiocytic Disorders, Malignant research studies include Rohini Jain.
Last updated: